(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
20 November 2025 (20.11.2025)

WIPO | PCT

(10) International Publication Number
WO 2025/238528 A1

(51) International Patent Classification:
C07K 16/28 (2006.01) *A61P 13/12* (2006.01)
A61K 39/395 (2006.01) *C07K 16/46* (2006.01)
A61P 3/00 (2006.01) *C12N 15/13* (2006.01)
A61P 7/06 (2006.01)

(21) International Application Number:
PCT/IB2025/054978

(22) International Filing Date:
13 May 2025 (13.05.2025)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
24175368.0 13 May 2024 (13.05.2024) EP

(71) Applicant: **EPOK THERAPEUTICS INC.** [CA/CA]; 333 Bay Street / Suite 2400, Toronto, Ontario M5H 2T6 (CA).

(72) Inventors: **BLAZER, Levi L.**; c/o EPOK THERAPEUTICS INC., 333 Bay Street, Suite 2400, Toronto, Ontario M5H 2T6 (CA). **ADAMS, Jarrett**; c/o EPOK THERAPEUTICS INC., 333 Bay Street, Suite 2400, Toronto, Ontario M5H 2T6 (CA). **MOE, Orson W.**; c/o EPOK THERAPEUTICS INC., 333 Bay Street, Suite 2400, Toronto, Ontario M5H 2T6 (CA). **SIDHU, Sachdev**; c/o EPOK THERAPEUTICS INC., 333 Bay Street, Suite 2400, Toronto, Ontario M5H 2T6 (CA).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UY, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report (Art. 21(3))*
— *with sequence listing part of description (Rule 5.2(a))*
— *in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE*

(54) Title: TETRAVALENT AGONISTS OF ERYTHROPOIETIN RECEPTOR



Fig. 1

(57) Abstract: It forms an object of the present invention a tetravalent antibody construct capable of selectively binding with high affinity to human EPOR, acting as a hEPOR agonist. It forms a further object said antibody for use in the treatment of kidney diseases and anemias.

WO 2025/238528 A1